TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1767322
Drug: Placebo (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (same amount of solution as cerebrolysin)
Study: 25488963
Drug: Linifanib 17.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linifanib 17.5 mg once daily
Study: 26931117
Drug: Sorafenib 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib 400 mg twice daily
Study: 23274057
Drug: Non-medical prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-medical prescription stimulants (NMPS)
Study: 23274057
Drug: Non-medical prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-medical prescription stimulants (NMPS) with alcohol
Study: 23274057
Drug: Past year
Normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Past year drinkers who did not use prescription stimulants
Study: 23274057
Drug: Concurrent NMPS
Normalized name: NMP
DrugBank: Methyl pyrrolidone (DB12521)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent NMPS and alcohol users (use over the past year but not at the same time)
Study: 13680313
Drug: Calcitriol, fluoride,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitriol, fluoride, calcium, clodronate, etidronate, hormone replacement therapy, pamidronate, strontium, tiludronate, vitamin D
Study: 10960802
Drug: Vinorelbine as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine as a single agent
Study: 25779885
Drug: No prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No prophylactic antibiotics (158 patients, 40.0%)
Study: 23821974
Drug: Dexamethasone 10/5/5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 10/5/5 mg (immediately postoperatively and on day 1 and 2)
Study: 23821974
Drug: Dexamethasone 20/10/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 20/10/10 mg
Study: 16283318
Drug: Amitriptyline (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (20 mg daily)
Study: 12169073
Drug: Sertraline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50 to 200 mg/d for 24 weeks)
Study: 7614529
Drug: OPTI‐SOAK Conditioning
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPTI‐SOAK Conditioning Solution
Study: 7614529
Drug: Boston Advance
Normalized name: Bausch+Lomb Boston Advance Cleaner
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boston Advance Conditioning Solution
Study: 7614529
Drug: Boston Conditioning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boston Conditioning Solution
Study: 7614529
Drug: Barnes‐Hind Wetting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barnes‐Hind Wetting and Soaking Solution
Study: 7614529
Drug: Total Cleaning,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total Cleaning, Wetting & Soaking Solution
Study: 102114
Drug: Thyrotropin-releasing hormone
Normalized name: thyrotropin-releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyrotropin-releasing hormone (TRH) 80 mg daily for 3 weeks
Study: 102114
Drug: Amitriptyline 100
Normalized name: amitriptyline 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 100 mg daily for 3 weeks
Study: 29874805
Drug: Cod‐PC (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cod‐PC (6 g/day of proteins from cod residuals as presscake meal)
Study: 29874805
Drug: Cod‐PCW (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cod‐PCW (6 g/day of proteins from cod residuals as presscake and stickwater meal)
Study: 3769702
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets (control)
Study: 27021752
Drug: Collaborative Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collaborative Care (CC) intervention
Study: 24390777
Drug: Daily school
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily school physical education (PE) for 40 minutes
Study: 22071290
Drug: Nutritional supplementation
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplementation (energy and protein enriched diet, oral nutritional support, calcium‐vitamin D supplement, telephone counselling by a dietician)
Study: 19602584
Drug: AICA-riboside infusion
Normalized name: nicotinamide ribotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: AICA-riboside infusion (2 mg x min(‐1) x dl(‐1))
Study: 19602584
Drug: AICA-riboside infusion
Normalized name: nicotinamide ribotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: AICA-riboside infusion combined with caffeine (90 microg x min(‐1) x dl(‐1); n = 6)
Study: 19602584
Drug: AICA-riboside infusion
Normalized name: nicotinamide ribotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: AICA-riboside infusion combined with l-NMMA (0.4 mg x min(‐1) x dl(‐1); n = 6)
Study: 19602584
Drug: AICA-riboside infusion
Normalized name: nicotinamide ribotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: AICA-riboside infusion
Study: 17827465
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus thoracic radiation
Study: 9646621
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg simvastatin
Study: 15924805
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg simvastatin + 200 mg fenofibrate
Study: 8703644
Drug: Enalaprilat 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalaprilat 0.25 mg h‐1
Study: 8703644
Drug: Enalaprilat 0.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalaprilat 0.50 mg h‐1
Study: 31691462
Drug: Double-blind treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-blind treatment (caplacizumab)
Study: 31691462
Drug: Placebo (during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (during double-blind treatment)
Study: 22313580
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg depo‐methylprednisolone + 0.5% lidocaine
Study: 17464703
Drug: Atomoxetine (0.8-1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine (0.8-1.8 mg kg(‐1) day(‐1))
Study: 17464703
Drug: Methylphenidate (0.2-0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (0.2-0.6 mg kg(‐1) day(‐1))
Study: 10204833
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg ascorbic acid
Study: 10204833
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg ascorbic acid
Study: 25399658
Drug: Thienopyridine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thienopyridine treatment
Study: 9543613
Drug: Cimetidine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (400 mg b.d. for 7 days starting 5 days before chemotherapy)
Study: 7932825
Drug: Chronomodulated drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronomodulated drug delivery (schedule B)
Study: 7932825
Drug: Constant-rate drug
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant-rate drug delivery (schedule A)
Study: 3284943
Drug: Intravenous APSAC
Normalized name: APSAC
DrugBank: Anistreplase (DB00029)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous APSAC (30 U in 2 to 4 min)
Study: 22519866
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate (50 mg.kg(‐1) followed by continuous infusion of 15 mg.kg(‐1).h(‐1))
Study: 20497133
Drug: Low-exposure ethanol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-exposure ethanol (targeted breathalyzer = 0.040 g/dl)
Study: 20497133
Drug: High-exposure ethanol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-exposure ethanol (targeted breathalyzer = 0.100 g/dl)
Study: 18375328
Drug: Continuous extrapleural
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous extrapleural infusion of ropivacaine 0.2% at a rate of 6 mL/h
Study: 18375328
Drug: Continuous extrapleural
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous extrapleural infusion of ropivacaine 0.2% at a rate of 9 mL/h
Study: 18375328
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of the two dosing regimens (6 mL/h vs 9 mL/h)
Study: 16161996
Drug: Intravenous application
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous application of compound 19 (BIBN4096)
Study: 16161996
Drug: CGRP receptor
Normalized name: CGRP
DrugBank: Calcitonin gene-related peptide (DB06379)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGRP receptor antagonists (compound 19)
Study: 10353516
Drug: Daily dapsone
Normalized name: Dapsone
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily dapsone (2 mg/kg)
Study: 10353516
Drug: Daily dapsone
Normalized name: Dapsone
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily dapsone (1 mg/kg)
Study: 10353516
Drug: Weekly dapsone
Normalized name: Dapsone
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly dapsone (4 mg/kg)
Study: 10353516
Drug: Daily dapsone
Normalized name: Dapsone
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily dapsone (1 mg/kg) and Daily dapsone (2 mg/kg)
Study: 8440768
Drug: 0.5 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg/day tirilazad mesylate
Study: 8440768
Drug: 1.0 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg/kg/day tirilazad mesylate
Study: 8440768
Drug: 2.0 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg/kg/day tirilazad mesylate
Study: 8440768
Drug: 4.0 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.0 mg/kg/day tirilazad mesylate
Study: 8440768
Drug: 6.0 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.0 mg/kg/day tirilazad mesylate
Study: 8440768
Drug: Intravenous normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous normal saline placebo
Study: 3092653
Drug: Enprostil (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enprostil (dose not specified)
Study: 27714459
Drug: Arthrocentesis +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arthrocentesis + Sodium hyaluronate (SH) injection
Study: 22729967
Drug: DPA supplementation
Normalized name: DPA
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DPA supplementation (8 g of pure DPA)
Study: 22729967
Drug: EPA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA supplementation (8 g of pure EPA)
Study: 22729967
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (olive oil)
Study: 21708185
Drug: Minimum 20
Normalized name: sipuleucel-T
DrugBank: Sipuleucel-T (DB06688)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimum 20 minutes of daily commuter cycling during 8 weeks
Study: 17869446
Drug: oral uracil
Normalized name: uracil
DrugBank: Uracil (DB03419)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral uracil and tegafur (UFT) plus LV (UFT+LV)
Study: 14521531
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (20 mg per day for 10 days)
Study: 14521531
Drug: Placebo (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (750 mg glucose per day for 10 days)
Study: 10856481
Drug: 75 IU
Normalized name: Follitropin Beta 75 IU/0.5 ML Injection Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 IU subcutaneous (s.c.) recombinant FSH
Study: 10856481
Drug: 150 IU
Normalized name: Follitropin Beta 150 IU/0.5 ML Injection Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 IU subcutaneous (s.c.) recombinant FSH
Study: 10856481
Drug: 225 IU
Normalized name: Ascorbic Acid/Calcium Pantothenate/Cyanocobalamin/Iron/Niacin/Pyridoxine/Riboflavin/Thiamine/Vitamin A/Vitamin D/Vitamin E/Zinc 200 MG-18.4 MG-0.005 MG-12 MG-100 MG-4.1 MG-10 MG-0.3 MG-10000 IU-400 IU-225 IU-1.5 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 225 IU subcutaneous (s.c.) recombinant FSH
Study: 10856481
Drug: 150 IU
Normalized name: Follitropin Beta 150 IU/0.5 ML Injection Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 IU intramuscular (i.m.) recombinant FSH
Study: 25231677
Drug: Calcium 1,200
Normalized name: Calcium 1,200mg Oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium 1,200 mg/day
Study: 23652739
Drug: Herbst multibracket
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbst multibracket (MB) treatment
Study: 21612746
Drug: Roflumilast (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roflumilast (500 μg)
Study: 21612746
Drug: Warfarin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (25 mg) with Roflumilast
Study: 21612746
Drug: Warfarin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (25 mg) with Placebo
Study: 15575918
Drug: Everolimus (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (3 mg/day)
Study: 16433771
Drug: Azathioprine (1-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine (1-3 mg/kg/day)
Study: 15541209
Drug: Trospium chloride
Normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trospium chloride 20-mg tablets, administered twice daily
Study: 15541209
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered twice daily
Study: 11775562
Drug: 0.6 ml
Normalized name: ethanol 0.6 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 ml (5700 IU) of nadroparin
Study: 11775562
Drug: 1.0 ml
Normalized name: digoxin 0.25 mg in 1.0 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 ml (9500 IU) of nadroparin
Study: 9280815
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (reviparin sodium)
Study: 9280815
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (adjusted-dose, intravenous)
Study: 7839476
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg nebulized budesonide
Study: 31698359
Drug: Subcutaneous AT
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous AT (SAT) mass, Visceral AT (VAT) mass, and gene expression in SAT
Study: 31698359
Drug: Subcutaneous AT
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous AT (SAT) mass
Study: 16778652
Drug: Collagen implant
Normalized name: Collagen implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagen implant
Study: 14523272
Drug: HIV-RNA level
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV-RNA level under 50 copies/ml
Study: 10801756
Drug: L-arginine (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (9 g daily for 1 month)
Study: 1425206
Drug: Levodropropizine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodropropizine (60 mg t.i.d. for 7 days)
Study: 24241212
Drug: Linifanib at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linifanib at a maximum tolerated dose of 0.25 mg/kg
Study: 21067470
Drug: 200 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 μg dexamethasone cipecilate
Study: 15739076
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba (120 mg, single dose)
Study: 15739076
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba (120 mg/day for 6 weeks)
Study: 7629414
Drug: Unbuffered lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unbuffered lidocaine (L)
Study: 2611076
Drug: nalbuphine 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: nalbuphine 0.3 mg kg‐1
Study: 2611076
Drug: morphine 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine 0.15 mg kg‐1
Study: 3880992
Drug: Placebo saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo saline solution
Study: 30887731
Drug: 1-L·kg·min-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-L·kg·min-1
Study: 30887731
Drug: 2-L·kg·min-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-L·kg·min-1
Study: 21609504
Drug: Assessment with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assessment with feedback during individual treatment (using Readiness to Change Questionnaire and Personal Resources Diagnostic System)
Study: 21609504
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment without within treatment assessment with feedback
Study: 21609504
Drug: Assessment with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assessment with feedback during individual treatment
Study: 17764789
Drug: Transcutaneous immunisation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous immunisation (TCI) with live-attenuated measles vaccine ROUVAX
Study: 15075414
Drug: Self-reported medications
Normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-reported medications
Study: 11251037
Drug: Molecular adsorbent
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Molecular adsorbent recirculating system (MARS) treatment for 6-8 hours
Study: 22534479
Drug: MARS treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: MARS treatment
Study: 9291514
Drug: Emergency physicians
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emergency physicians prescribing narcotics (codeine or oxycodone compounds)
Study: 9291514
Drug: Overall physician
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall physician willingness to prescribe stronger medications than acetaminophen or NSAIDs
Study: 9291514
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of narcotic prescriptions for 2-year-old vs 22-year-old patients
Study: 9291514
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of narcotic prescriptions between pediatricians and family practice physicians
Study: 2453700
Drug: Allapinin (0.39
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allapinin (0.39 mg/kg)
Study: 2453700
Drug: Allapinin (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allapinin (doses > 0.32 mg/kg)
Study: 2453700
Drug: Allapinin (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allapinin (doses > 0.42 mg/kg)
Study: 27631142
Drug: Citalopram (20-60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (20-60 mg/d) for 8-14 weeks
Study: 22392835
Drug: 100% oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100% oxygen inhalation at a rate of 15 L/min for 3 min
Study: 15859361
Drug: Celecoxib (CE)
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib (CE) 200 mg administered in refracted doses
Study: 11836044
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens 0.6 mg plus sequential medrogestone 5 mg (CEE/M)
Study: 7538237
Drug: Bicalutamide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicalutamide (50 mg once daily) plus LHRH analogue therapy
Study: 7538237
Drug: Flutamide (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide (250 mg three times daily) plus LHRH analogue therapy
Study: 7538237
Drug: Bicalutamide plus
Normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bicalutamide plus LHRH analogue therapy
Study: 7538237
Drug: Flutamide plus
Normalized name: Flutamide
DrugBank: Flutamide (DB00499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flutamide plus LHRH analogue therapy
Study: 1835650
Drug: Vaginal ring
Normalized name: NuvaRing Vaginal Ring
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal ring releasing 10 mg of natural progesterone per 24 h
Study: 6217949
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide (0.04 mg per dose, 3 times daily)
Study: 6217949
Drug: Salbutamol (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (0.2 mg per dose, 3 times daily)
Study: 31063869
Drug: Oxytocin in
Normalized name: Oxytocin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin in combination with Alcohol Behavioral Couples Therapy (ABCT)
Study: 31063869
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in combination with Alcohol Behavioral Couples Therapy (ABCT)
Study: 17985808
Drug: Shamanic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shamanic treatment during 5 treatment visits
Study: 12700990
Drug: Osmotic laxatives
Normalized name: HYPEROSMOTIC LAXATIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osmotic laxatives and prokinetic drugs (e.g., erythromycin, acetylcholinesterase inhibitors)
Study: 12700990
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of epidural anesthesia, sparse use of i.v. opioids, early food intake, and laxatives/prokinetics
Study: 8666632
Drug: Low-energy extracorporeal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-energy extracorporeal shock-wave therapy (3000 impulses of 0.08 mJ/mm2)
Study: 24599578
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of aerobic exercise (STAN; 25 to 30 minutes, thrice weekly)
Study: 24599578
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose of aerobic exercise (HIGH; 50 to 60 minutes, thrice weekly)
Study: 24599578
Drug: Combined dose
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined dose of aerobic and resistance exercise (COMB; 50 to 60 minutes, thrice weekly)
Study: 24599578
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of aerobic exercise (STAN)
Study: 24599578
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose of aerobic exercise (HIGH) and Combined exercise (COMB)
Study: 1964663
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (LMW heparin)
Study: 3981950
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UF heparin)